



Research Grant Report Form

Name and origin of applicants:

Kristjan Karason,
Head of Transplant Cardiology
Sahlgrenska University hospital, Transplant Institute
413 45 Gothenburg, Sweden

Purpose of research project granted:

Heart transplantation in inflammatory cardiomyopathy knowledge acquisition
(HATTRICK)

Amount granted:

75.000 DKK

Report of scientific progress:

Kaj Anker Jørgensen
Medical director
Scandiatransplant
Århus, Denmark

Kristjan Karason MD PhD
Transplant Institute
Sahlgrenska University Hospital
413 45 Gothenburg, Sweden

April 16th 2021

REF: Research grant for the HATTRICK study

Dear Director Jørgensen

We greatly appreciate the grant we received from Scandiatransplant with respect to the HATTRICK study.

The aim of the study is to investigate patients with cardiac sarcoidosis (CS) and giant cell myocarditis (GCM), who undergo heart transplantation (HTx) since uncertainty still prevails whether people with

these diseases are optimal HTx candidates do to the risk for disease recurrence and poor outcome. These are rare diseases and to be able to increase our knowledge concerning the characteristics of these conditions pre-HTx and to offer an extensive overview of the outcome post-HTx we need to collect the experience from several centers. Thus, a Nordic study including multiple centers will clear the ambiguity surrounding the post-transplant outcome of subjects with these diseases.

As part of the project we have written a meta-analysis concerning the post-HTx outcomes of patients with CS and GCM, which has now been submitted and is under peer review at a medical scientific journal. With help of the grant we have been able to establish an eCRF, which all Nordic centers can use to enter data.

All data on patients with CS and GCM from Gothenburg and Oslo have been entered to the database.

Lund has also started including patients. However, we have had some problems activating the centers in Denmark and Finland, but are now exerting severe pressure on these centers to fulfill their commitment to the study.

We have good contacts with key persons at the centers in Copenhagen, Aarhus, and Helsinki, and all have promised to deliver data during the second quarter this year. Thus, we anticipate that all data will be entered to the database before the summer 2021 and we will be able to accomplish a clean database during the third quarter 2021. Data analysis will start as soon as we have a complete a clean database, which will include all patients that have undergone HTx due to CS or GCM in the Nordic countries. We expect that this can be performed during summer or early autumn 2021. Patients that have undergone HTx due to CS och GCM will be compared with patients that have undergone HTx due to other heart failure etiologies matched for age, sex, and place of residence. We expect to be able to write a manuscript during the fourth quarter 2021, which will be submitted to a peer review scientific journal.

Once again, many thanks for the financial support that we have received from Scandiatransplant, which will allow us to investigate this important question. Please contact me if you have further questions.

Best regards,

Kristjan Karason MD, PhD,

Director of Transplant Cardiology
Sahlgrenska University Hospital Gothenburg,
Sweden

Email: kristjan.karason@vgregion.se

Mobile phone +46 (0) 739451560
